110P Updated efficacy and safety of entrectinib in patients (pts) with NTRK fusion-positive (NTRK-fp) NSCLC
ANNALS OF ONCOLOGY(2022)
摘要
Neurotrophic receptor tyrosine kinase (NTRK) gene fusions are oncogenic drivers in many solid tumours, including NSCLC. Entrectinib (a CNS-active, potent TRK inhibitor) has shown efficacy in pts with NTRK-fp NSCLC from the STARTRK-2 (NCT02568267) and STARTRK-1 (NCT02097810) trials: objective response rate (ORR) was 69% (n=9/13; 31 Oct 2018 cutoff). We present an updated analysis in this cohort.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要